Sign in

    Bob Ford

    Managing Director and Senior Equity Research Analyst at Bank of America

    Bob Ford is a Managing Director and Senior Equity Research Analyst at Bank of America, specializing in the healthcare and biotechnology sectors with a particular focus on pharmaceutical, biotechnology, and diagnostics companies. Over his extensive career, he has covered leading life sciences companies such as Abbott Laboratories, Thermo Fisher Scientific, and Illumina, and has received recognition for his stock picking with consistently strong success rates and high rankings on industry platforms. Ford started his Wall Street career in the early 2000s after earning his MBA and has since held prominent analyst roles at Lehman Brothers and Merrill Lynch before joining Bank of America in 2009. He maintains FINRA Series 7, 63, and 86/87 securities licenses and is frequently recognized for his stock-picking acumen with multiple placements in Institutional Investor All-America Research Team rankings.

    Bob Ford's questions to Arcos Dorados Holdings (ARCO) leadership

    Bob Ford's questions to Arcos Dorados Holdings (ARCO) leadership • Q1 2025

    Question

    Bob Ford asked about the company's pricing strategy across its various markets and the net impact of the Argentine peso's real appreciation on G&A expenses and overall profitability.

    Answer

    CFO Mariano Tannenbaum reiterated the strategy of aligning price increases with inflation to protect traffic. He explained that while the Argentine peso's appreciation negatively impacts corporate G&A expenses based there, this is more than offset by the positive effect on the Argentine operation's profitability, resulting in a net positive impact for Arcos Dorados on a consolidated basis.

    Ask Fintool Equity Research AI